Background

The current standard of care for non‑muscle‑invasive bladder cancer combines chemotherapy—such as cisplatin, gemcitabine, 5‑fluorouracil, or mitomycin‑C—with radiation. Chemotherapy directly kills cancer cells or inhibits their proliferation, but it is associated with systemic toxicities and resistance. Consequently, there is a growing need for more selective therapeutic strategies.

Mechanism of Immunotherapy

Pembrolizumab (Keytruda) is an immune‑checkpoint inhibitor that blocks the PD‑1 receptor, enabling T cells to recognize cancer cells. Unlike conventional chemotherapy, this approach activates a systemic immune response, offering the potential for durable tumor control. Immunotherapy may also remodel the tumor microenvironment, creating the possibility of synergistic effects with radiation therapy.

Trial Design and Objectives

This Phase 2 trial is sponsored by the NCI and compares pembrolizumab plus radiation against a chemoradiotherapy control arm. The primary endpoints are progression‑free survival and safety, and enrollment began on June 3 2025 for patients with non‑muscle‑invasive bladder cancer. The study is actively recruiting, and the projected completion date has not been disclosed.

Expected Benefits and Impact

If the pembrolizumab‑radiation combination demonstrates a higher tumor‑clearance rate than chemotherapy, the standard‑of‑care paradigm could shift dramatically. This regimen may offer effective disease control with reduced toxicity for elderly patients or those resistant to chemotherapy. Success would likely expand the immune‑oncology market and prompt a re‑configuration of the bladder‑cancer therapeutic portfolio.